A T-independent pathway of B cell responses to oligomannosyl antigens of HIV-1
A T-independent pathway of B cell responses to oligomannosyl antigens of HIV-1
批准号:
8703221
负责人:
DENONG WANG
金额:
$75.09万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-13 至 2016-07-31
关键词:
AntibodiesAntibody FormationAntibody RepertoireAntigensB cell repertoireB-Cell ActivationB-Lymphocyte SubsetsB-LymphocytesBindingBlood CirculationC-Type LectinsCD19 geneCD209 geneCarbohydratesCell LineageCellsDevelopmentDimensionsEpitopesFluorescence-Activated Cell SortingGlycoproteinsGreater sac of peritoneumHIVHIV Envelope Protein gp120HIV-1HumanHybridomasImmunizationImmunoglobulin GImmunoglobulin MInfectionMannoseModelingMonoclonal AntibodiesMusPTPRC genePathway interactionsPhenotypePolysaccharidesPopulationProductionReceptors, Antigen, B-CellResearch PersonnelRoleSignal TransductionSpecificitySpleenStaining methodStainsSurfaceTechnologyTissuesVaccinesVirionantigen bindingbasecongenicdefined contributiondesignhuman subjecthumanized monoclonal antibodiesinterestmouse modelneutralizing antibodynovelpathogenperipheral bloodreceptor bindingresearch studyresponsesugarvaccination strategy
中文摘要
描述(由申请人提供):作为广泛HIV-1中和抗体(2G 12)表位的特定寡甘露糖簇的发现激发了对基于碳水化合物的HIV-1疫苗的极大兴趣。最近,我们在幼稚B细胞库中鉴定了Man 9簇结合B细胞(BMan 9+)的显著群体。在人外周血中,该群体构成约12%的CD 19 + CD 45 + B细胞。类似地,BMan 9+细胞占小鼠腹腔(PerC)中B-1a(CD 19 + CD 5+)B细胞的10-12%。使用碳水化合物微阵列来筛选人类血液循环中的抗聚糖抗体,我们揭示了在HIV-1感染和未感染的人类受试者中存在显著量的抗Man 9簇抗体(IgM和IgG同种型)。然而,在HIV-1感染的受试者中,抗Man 9簇抗原的IgG抗体水平显著增加。这些发现表明,在预先存在的B细胞库中存在进化上保守的BMan 9+细胞群体,其容易与HIV-1碳水化合物反应。由于抗原结合B细胞群比通常观察到的抗原特异性B细胞群大得多,我们提出这些B细胞不仅表达常规的Ig-B细胞受体,而且表达非Ig-甘露糖结合受体,如DC-SIGN。在与可溶性gp 120糖蛋白或天然HIV病毒体结合后,这些细胞进入独特的T-非依赖性B细胞活化途径,即,C型凝集素参与的T细胞非依赖性1型反应(TI-1c)。在这项研究中,我们计划利用完善的IgH同种异型小鼠模型,以进一步表征TI-1c途径的B细胞活化和抗体反应的寡甘露糖抗原的HIV-1。具体地,我们将a)表征BMan 9+细胞的B细胞谱系分布和起源(目标1); B)检测B-1和B-2谱系对天然抗体库中抗寡甘露糖抗体产生的贡献(目标2); c)检测对HIV-1的合理设计的TI-1c寡甘露糖抗原的获得性抗体应答(目标3);和d)确定疫苗引发的抗Man 9簇抗体的精细特异性和潜在的HIV-1中和活性(目的4)。总之,我们提出并设计了实验来表征B细胞活化的TI-1c途径和对HIV-1寡甘露糖基抗原的抗体应答。本研究获得的信息可能对开发针对HIV-1和表达寡甘露糖基糖部分的其他病原体的新疫苗接种策略具有指导意义。
英文摘要
DESCRIPTION (provided by applicant): Discovery of a specific oligomannose cluster as the epitope of a broadly HIV-1 neutralizing antibody (2G12) has stimulated substantial interest in carbohydrate-based HIV-1 vaccines. Recently, we identified a significant population of Man9-cluster-binding B cells (BMan9+) in the naive B cell repertoires. In human peripheral blood, this population constitutes approximately 12% CD19+CD45+ B cells. Similarly, BMan9+ cells represent 10-12% of B-1a (CD19+CD5+) B cells in the mouse peritoneal cavity (PerC). Using carbohydrate microarrays to screen anti-glycan antibodies in human blood circulation, we revealed that significant amounts of anti-Man9-cluster antibodies (IgM and IgG isotypes) are present in both HIV-1 infected and non-infected human subjects. However, the levels of IgG antibodies to Man9-cluster antigen are markedly increased in the HIV-1 infected subjects. These findings suggest that there is an evolutionally conserved BMan9+ cell population present in the pre-existing B cell repertoires that is readily reactive with HIV-1 carbohydrates. Since thi population of antigen-binding B cells is extraordinarily larger than the generally observed antigen-specific B cell populations, we propose that these B cells express not only conventional Ig-B cell receptors but also non-Ig-mannose-binding receptor(s), such as DC-SIGN. Upon binding to either soluble gp120 glycoprotein or the native HIV virions, these cells enter into a unique T-independent pathway of B cell activation, i.e., the C-type-lectin-engaged T-independent type 1 response (TI-1c). In this study, we plan to make use of well-established IgH-allotypic mouse models to further characterize the TI-1c pathway of B cell activation and antibody responses to oligomannosyl antigens of HIV-1. Specifically, we will a) characterize the B cell lineage distribution and origin of the BMan9+ cells (Aim 1); b) examine contributions of B-1 and B-2 lineages to production of anti-oligomannose antibodies in the natural antibody repertoires (Aim 2); c) Examine the acquired antibody responses to rationally designed TI-1c oligomannosyl antigens of HIV-1 (Aim 3); and d) Determine the fine specificity and potential HIV-1 neutralization activity of vaccine-elicited anti-Man9-cluster antibodies (Aim 4). In summary, we propose and design experiments to characterize the TI-1c pathway of B cell activation and antibody responses to oligomannosyl antigens of HIV-1. Information obtained by this study is likely instructive to development of novel vaccination strategies against HIV-1 and other pathogens that express oligomannosyl sugar moieties.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomas
-
批准号:10436334
-
项目类别:
-
资助金额:$30.47万
-
财政年份:2021
-
负责人:DENONG WANG
-
依托单位:
Oligomannose antigens as conserved immunological targets of Non-Hodgkin lymphomas
-
批准号:10267450
-
项目类别:
-
资助金额:$27.12万
-
财政年份:2021
-
负责人:DENONG WANG
-
依托单位:
IMMUNOGENIC SUGAR MOIETIES OF HCMV
-
批准号:9245147
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2017
-
负责人:DENONG WANG
-
依托单位:
B-1 B cell responses to oligomannosyl antigens of HIV-1
-
批准号:9078722
-
项目类别:
-
资助金额:$88.36万
-
财政年份:2015
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:8125080
-
项目类别:
-
资助金额:$42.75万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7638573
-
项目类别:
-
资助金额:$40.3万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7877784
-
项目类别:
-
资助金额:$45.24万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7479360
-
项目类别:
-
资助金额:$40.39万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7692616
-
项目类别:
-
资助金额:$15.8万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
Immunogenic sugar moieties of prostate cancers
-
批准号:7281012
-
项目类别:
-
资助金额:$42.24万
-
财政年份:2007
-
负责人:DENONG WANG
-
依托单位:
T-INDEPENDENT IGA INDUCTION AND HIV-1 VACCINATION
-
批准号:6170336
-
项目类别:
-
资助金额:$24.83万
-
财政年份:1999
-
负责人:DENONG WANG
-
依托单位:
T-INDEPENDENT IGA INDUCTION AND HIV-1 VACCINATION
-
批准号:2873465
-
项目类别:
-
资助金额:$24.54万
-
财政年份:1999
-
负责人:DENONG WANG
-
依托单位:
海外基金